FDA approved Cablivi in 2019 for usage in adults with acquired thrombocytopenic purpura (autoimmune blood disorder), and this has increased global demand among patients looking to buy Cablivi in India. It has expanded its indication to children which will be covered as follows.

Essential Insights of Cablivi

The von willebrand factor is a type of protein found in your blood that acts as a glue to stop bleeding when you are injured. Cablivi is composed of a core component called Caplacizumab is a small antibody aimed to attach to von willebrand factor in a way to stop the gluing effect in order to reduce the blood clots in the blood vessels, which has led many patients to explore options to buy Caplacizumab in India. This results in increased levels of platelets because they no longer participate in blood clots.

von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy, and is often accessed by patients who plan to Buy Caplacizumab online in India through regulated channels.

Latest updates by FDA in 2026

Cablivi for adults

  • Cablivi (Caplacizumab) was approved for adult patients with aTTP in 2019 based on a clinical trial called HERCULES trial, and the Cablivi price in India remains a key consideration for patients evaluating treatment options.

For children:

  • Recently the FDA announced its approval in children aged 12 years and older. This expansion was based on retrospective chart review study, but not traditional clinical trials. This retrospective study included 30 pediatric patients aged 2-18 years, and the Caplacizumab price in India may vary depending on access pathways.
  • Results showed that 80% of the patients achieved clinical remission (symptoms lessened) and improved LDH levels (marker of red blood cell breakdown) for around 30 days, encouraging more patients to Buy Cablivi online in India through compliant import programs.
  • The most common side-effects include nose bleeds, headache and gingival bleeding.
  • Patients with underlying coagulopathies like impaired clotting abilities or who are taking blood thinning medicines such as antiplatelet agents or anticoagulants have the bleeding risk, and they should consult doctors before evaluating the price of cablivi in india.
  • Patients are advised to stop the therapy if they notice clinically prominent bleeding.
  • Cablivi is not recommended to patients 7 days before elective surgery or any invasive procedures. Also, patients who have the allergic reaction to any of its components should confirm with the doctor for its usage.
  • The benefits of administering Cablivi in children include fast clot prevention, reduced risk of organ damage and more targeted based treatment.
  • FDA also recommended the usage of Cablivi with immunosuppressive therapy alongside plasma exchange.
  • Cablivi has not been treated with the name “Orphan Drug Designation” for the treatment of pediatric aTTP, reflecting both the rarity of the condition and the unmet medical need in this population. The designation is intended to encourage the development and availability of therapies for rare diseases by providing regulatory and development incentives.

Why does Cablivi’s approval matter most?

  1. It addresses serious and emergency conditions like organ failure, stroke and death where small clots can form into blood clots within a shorter duration.
  2. It is the first-targeted therapy in children with aTTP to treat the cause indirectly and aims to target the cancer cells.
  3. Patient recovery is faster such as platelets coming back to normal levels because of early clot formation. It reduces the chances of recurrence. Hence these factors reduce the hospital stays.
  4. It supports real-world, rare disease innovation as strong evidence doesn’t always need large clinical trials for approvals.
  5. It reduces healthcare burden showing its therapeutic advantages to patients and hospitals.

Though it’s just a minor label change, its expansion includes a wide range of children to receive the treatment, and many patients now explore ways to buy Cablivi in India through authorized suppliers. A shift from traditional to Cablivi shows a modern aggressive early intervention model. Reach out to us for our more updated information at 24/7QualityMeds.

References: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-therapy-rare-blood-disorder-pediatric-patients-12-years-and-older